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Non-steroidal anti-inflammatory drugs (NSAIDs) can damage the small intestine, mainly
through an involvement of enteric bacteria. This study examined the pathophysiology
of NSAID-associated intestinal lesions in a rat model of diclofenac-enteropathy and
evaluated the effect of rifaximin on small bowel damage. Enteropathy was induced in 40-
week old male rats by intragastric diclofenac (4 mg/kg BID, 14 days). Rifaximin (delayed
release formulation) was administered (50 mg/kg BID) 1 h before the NSAID. At the
end of treatments, parameters dealing with ileal damage, inflammation, barrier integrity,
microbiota composition, and TLR-NF-κB-inflammasome pathway were evaluated. In
addition, the modulating effect of rifaximin on NLRP3 inflammasome was tested in an
in vitro cell system. Diclofenac induced intestinal damage and inflammation, triggering
an increase in tissue concentrations of tumor necrosis factor and interleukin-1β, higher
expression of TLR-2 and TLR-4, MyD88, NF-κB and activation of caspase-1. In addition,
the NSAID decreased ileal occludin expression and provoked a shift of bacterial phyla
toward an increase in Proteobacteria and Bacteroidetes abundance. All these changes
were counterbalanced by rifaximin co-administration. This drug was also capable of
increasing the proportion of Lactobacilli, a genus depleted by the NSAID. In LPS-
primed THP-1 cells stimulated by nigericin (a model to study the NLRP3 inflammasome),
rifaximin reduced IL-1β production in a concentration-dependent fashion, this effect
being associated with inhibition of the up-stream caspase-1 activation. In conclusion,
diclofenac induced ileal mucosal lesions, driving inflammatory pathways and microbiota
changes. In conclusion, rifaximin prevents diclofenac-induced enteropathy through both
anti-bacterial and anti-inflammatory activities.
Keywords: non-steroidal anti-inflammatory drugs, intestinal damage, intestinal bleeding, rifaximin,
enteroprotection, microbiota
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) represent one
of the most widely used classes of drugs (McGettigan and
Henry, 2013). Despite they confer important clinical benefits
across multiple indications, their use is associated with a wide
array of adverse events involving different organs and systems
(i.e., liver, kidney, cardiovascular system, skin, and gut). Those
concerning the gastrointestinal tract are the most common
and can cause both symptoms (dyspepsia, heartburn, and/or
abdominal discomfort) and lesions (mucosal erosions and/or
peptic ulcers, with their life-threatening ulcer complications of
bleeding and perforation) (Lanas and Hunt, 2006; Scarpignato
and Hunt, 2010). While NSAID-induced renal adverse events are
well-known, those concerning cardiovascular system (Grosser
et al., 2017; Patrono and Baigent, 2017) have been appreciated
only recently, after the rofecoxib fallout (DeMaria, 2004). Several
investigations (like the LOGICA and the GIRANO studies) have
shown that patients requiring NSAID therapy often display
gastrointestinal or/and cardiovascular risk factors (Lanas et al.,
2010; Vanderstraeten et al., 2016). Navigating through the
different risk factors and balancing them with the potential
benefits of NSAID therapy is clearly a difficult task.
Since in real life NSAID-associated gastrointestinal adverse
events largely exceed the cardiovascular ones (Lanas et al., 2015),
these drugs are frequently co-prescribed with proton pump
inhibitors (PPIs) to prevent NSAID-associated gastro-duodenal
damage and symptoms. According to currently available
guidelines (Tielemans et al., 2010; Scarpignato et al., 2015) the
co-administration of a gastroprotective compound (especially a
PPI) in NSAID users, holding one or more gastrointestinal risk
factors, has become the standard of care. Indeed, acid represents
the condition sine qua non for development of peptic ulcer and
related complications (Scarpignato and Pelosini, 1999). However,
since NSAID-enteropathy is not a pH-dependent phenomenon,
PPIs do not exert any protective activity beyond the duodenum
(Scarpignato et al., 2015).
Already, in the early 80s, some studies (Bjarnason et al., 1984,
1987) showed that NSAID-associated gastrointestinal damage
does extend also to the lower digestive tract. Later on, the clinical
impact of lower gastrointestinal damage and complications was
pointed out mainly by the first large prevention study with the
synthetic prostaglandin, misoprostol (i.e., the MUCOSA trial)
(Silverstein et al., 1995). In addition, the VIGOR trial (comparing
rofecoxib with naproxen) reported that more than 40% of
NSAID-related events occurred in the lower gastrointestinal tract
(Laine et al., 2003). Over the past decade, the overall pattern
of gastrointestinal events requiring hospitalization showed a
reverse trend, with a decrease of events located in the upper
gastrointestinal tract and a slight, albeit significant, increase in
those concerning the small and large bowel (Lanas et al., 2009).
The advent of new imaging techniques, such as video capsule
endoscopy, has allowed to gain new insights into NSAID-induced
intestinal damage, which appears to be site-dependent. The
pattern of mucosal injury, which can be found in up to 75% of
NSAID users (Graham et al., 2005; Maiden et al., 2005), ranges
from denuded areas (seen mainly in the proximal small bowel)
to the so-called mucosal breaks (erosions and ulcers), observed
in its distal part (Fujimori et al., 2010). Video capsule studies
and/or fecal calprotectin measurement clearly showed that PPIs
(like omeprazole) failed to prevent NSAID-associated intestinal
injury both in healthy volunteers (Goldstein et al., 2005, 2007;
Maiden et al., 2005) and patients (Graham et al., 2005). Recent
experimental (for review see Blackler et al., 2014) and clinical
(Fujimori et al., 2010; Washio et al., 2016) evidence suggest that
PPIs may actually aggravate NSAID injury in the small bowel.
The pathogenesis of small intestinal damage is still not
completely understood. The synthesis of endogenous mucosal
prostaglandins is inhibited by NSAID throughout the entire
gastrointestinal tract. However, other important pathogenic
factors, which contribute to damage, differ between the distal and
proximal regions of the gut (Bjarnason et al., 2018). Indeed, in the
small bowel, the presence of bacteria and bile represent pivotal
triggers of the mucosal damage (Lanas and Scarpignato, 2006;
Scarpignato, 2008; Blackler et al., 2014).
Bile acids (Petruzzelli et al., 2007) and inhibition of
endogenous mucosal prostanoids (Takeuchi et al., 2010) are both
implicated in the pathogenesis of NSAID-enteropathy. However,
current interest is focused on NSAID-induced alterations in
the gut microbiota, with consequent pathological activation
of the downstream inflammatory pathways (Scarpignato, 2008;
Bjarnason et al., 2018). Recent evidence (for review see
Pellegrini et al., 2017) points out the importance of nucleotide-
binding oligomerization domain leucine rich repeat and pyrin
domain-containing protein 3 (NLRP3) inflammasome in the
interaction amongst gut microbiome, intestinal barrier and
innate immune system, controlling in this way intestinal
homeostasis. A recent study (Higashimori et al., 2016) suggested
that NLRP3 inflammasome activation and associated IL-1β
release play a key role in NSAID-induced enteropathy.
The pathogenic role of enteric bacteria is supported by a large
experimental evidence (for review see Lanas and Scarpignato,
2006; Scarpignato, 2008; Blackler et al., 2014) showing that anti-
microbials attenuate NSAID-enteropathy. In humans (Bjarnason
et al., 1992), metronidazole (an anti-microbial targeting most
Gram-negative and Gram-positive anaerobic bacteria, Freeman
et al., 1997) was shown to reduce inflammation and blood loss
in NSAID users, thus suggesting a therapeutic role for anti-
microbials in this clinical setting. However, potential adverse
effects as well as the risk of drug resistance, associated with the use
of systemic anti-microbials, have so far precluded this interesting
approach (Lanas and Scarpignato, 2006).
Rifaximin (4-deoxy-4′-methylpyrido[1′,2′-1,2]imidazo [5,4-
c]rifamycin SV) is a semi-synthetic rifamycin derivative,
retaining the broad spectrum of anti-bacterial activity shared
by all the members of this drug class, but displaying a very
low (<1%) absorption from the gastrointestinal tract (Calanni
et al., 2014). Being poorly absorbed, it achieves intraluminal
concentrations much higher than those needed to inhibit enteric
bacteria. In addition, since it does not reach the systemic
circulation, the risk of anti-microbial resistance of adverse
effects is rather low (Scarpignato and Pelosini, 2005). Originally
approved for the treatment of gastrointestinal infections, the
use of rifaximin has been subsequently extended to other
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organic (like diverticular disease and hepatic encephalopathy)
and functional (such as irritable bowel syndrome and functional
constipation) diseases of the digestive system (Scarpignato and
Pelosini, 2005, 2006). Recently, the drug has been studied also in
patients with inflammatory bowel disease (Gionchetti et al., 2006;
Prantera et al., 2012).
Since rifaximin displays all the characteristics of an ideal
antibiotic for targeting enterobacteria (DuPont and Ericsson,
1993), its ability to prevent NSAID-induced intestinal damage
has been evaluated in both experimental (Ciobanu et al., 2014;
Fornai et al., 2016) and clinical (Scarpignato et al., 2017)
studies. In healthy volunteers indeed the number and severity
of diclofenac-induced intestinal lesions (as evaluated by video
capsule endoscopy) were reduced by co-administration of the
drug (Scarpignato et al., 2017).
To gain deep insights into the pathophysiology of NSAID-
associated lesions and to unravel the mechanisms of rifaximin
enteroprotective activity, we employed an animal model of
diclofenac-enteropathy and studied the effects of this poorly
absorbed antibiotic on mucosal lesions, inflammatory changes
and underlying molecular patterns as well as alterations of gut
microbiota induced by the NSAID. For this investigation, a
recently developed formulation (designed to bypass the stomach
and release the microgranules directly in the intestine) (Prantera
et al., 2012) was selected. It consists of microgranules of rifaximin,
coated with a gastric acid-resistant polymer, which increases
the intraluminal concentration of the drug, thus maximizing its
therapeutic efficacy.
MATERIALS AND METHODS
Study Design
The present study includes experiments based on morphological
(histological evaluations), molecular (biochemical and protein
expression assays), and microbiological (analysis of intestinal
microbiota composition) techniques to examine the protective
effects of rifaximin against NSAID-induced enteropathy in rats.
Groups of animals were randomly assigned to treatments with
drug vehicle, diclofenac, rifaximin or their combination. In
all experiments, investigators performing laboratory analyses
(which were made in duplicate) were blinded to the treatment
protocol. The sample size (n = 10 per group) was based on
the resource equation because the effects size was unknown
(Charan and Kantharia, 2013). Numbers of animals for each
experiment are detailed below and included in the figure
legends.
Animals
Experiments were performed on aged (40-week old) male Wistar
rats (500–600 g). The animals were fed standard laboratory
chow (Envigo, Udine, Italy) and tap water ad libitum, and were
not employed for at least 1 week after their delivery to the
laboratory. They were housed in solid-bottomed cages, equipped
wire-mesh bottom inserts to prevent coprophagy and located
in temperature-controlled rooms (at 22–24◦C and 50–60%
humidity) under a 12-h light cycle (06:00–18:00 h). Their care
and handling were in accordance with the provisions of the
European Community Council Directive 210/63/UE, recognized
and adopted by the Italian Government. The experiments were
approved by the Ethical Committee for Animal Experimentation
of the University of Pisa and by the Italian Ministry of Health.
The in vivo studies are reported in accordance with the ARRIVE
guidelines for reporting experiments involving animals (Kilkenny
et al., 2010).
Experimental Design
Enteropathy was induced by diclofenac in accordance with the
method previously developed in our laboratory (Fornai et al.,
2014). The dose of diclofenac was selected on the basis of
our previous study, in which preliminary experiments were
conducted to identify the timing and dose required to elicit lower
gastrointestinal injury. In that study, the effects of increasing
doses of diclofenac (2, 4, and 6 mg/kg), administered by gavage
twice daily, were assessed at days 7 and 14 of treatment (Fornai
et al., 2014). The results showed that diclofenac, administered
at 4 mg/kg BID, was able to produce the development of small
intestinal damage after 14 days – consistently with human data
(Scarpignato et al., 2017) – without causing excessive mortality
and, at the same time, remaining within the range of its inhibitory
activity for both COX isoenzymes.
Rifaximin (suspended in 1% methylcellulose, 1 ml/rat)
was administered as an extended intestinal release (E.I.R.)
formulation (50 mg/kg BID) 1 h before diclofenac for
14 days. Due to the high frequency of treatments, intragastric
administration of test drugs was performed in awake animals.
Twenty-four hours after the last dose of test drugs, non-fasted
rats were anesthetized with chloral hydrate. Blood samples
were collected by cardiac puncture from each animal for
hemoglobin measurement. Fecal pellets were collected directly
from the sigmoid colon and stored at −80◦C for calprotectin
measurement. The whole gastrointestinal tract was excised and
examined macroscopically. Samples of ileum were snap frozen
in liquid nitrogen and stored at −80◦C for subsequent analysis
of myeloperoxidase (MPO), malondialdehyde (MDA), tumor
necrosis factor (TNF) and interleukin-1β (IL-1β), as well as to
assess: the expression of toll-like receptors-2 and -4 (TLR-2, TLR-
4), and the myeloid-differentiation primary response gene 88
(MyD88), nuclear factor-κB (NF-κB) signaling and activation
of caspase-1, and the expression of the tight junction protein
occludin. Ileal samples were also processed for the evaluation of
the main bacterial phyla abundance as well as the prevalence of
the genus Lactobacillus, as reported below. Other portions of ileal
tissue were fixed in 10% formalin for subsequent evaluation of
microscopic damage.
The experimental groups were arranged as follows: Group 1:
animals treated with vehicle (control, n = 10); Group 2: animals
treated with diclofenac (n = 15); Group 3: animals treated with
diclofenac plus rifaximin (n = 12); Group 4: animals treated
with rifaximin alone (n = 12). Different numbers of animals for
each group of treatment were employed to compensate for the
different mortality rates affecting the groups of treatment (as
observed also in our previous studies, Fornai et al., 2014), in order
to ensure at least 10 animals per group at the end of treatments.
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Assessment of Intestinal Damage,
Tissue Inflammation, and Tissue
Cytokine Concentrations
Histology of the small bowel injury, tissue myeloperoxidase
(MPO, as an index of intestinal wall infiltration of
polymorphonuclear cells) and malondialdehyde (MDA,
reflecting membrane lipid peroxidation) concentrations were
measured according to previously adopted methods (Fornai
et al., 2016), detailed in Supplementary Material.
Tumor necrosis factor and Interleukin-1β (IL-1β) ileal
concentrations were quantitated according to the methodology
adopted in our laboratories (Fornai et al., 2016; Pellegrini
et al., 2016). Tissue preparation is described in Supplementary
Material.
Measurement of Fecal Calprotectin and
Blood Hemoglobin Concentration
Calprotectin, a calcium binding protein of neutrophil
granulocytes that correlates well with neutrophil infiltration
of the intestinal mucosa, was measured in fecal pellets, collected
as reported above whereas hemoglobin analysis was performed
on blood samples as previously described (Fornai et al., 2016)
(see Supplementary Material).
Western Blot Analyses
Specimens of mucosa were excised from ileum, weighed and
homogenized in lysis buffer, using a polytron homogenizer.
Mucosal homogenates were spun by centrifugation at 15,000 g
for 15 min at 4◦C, and the resulting supernatants were then
separated from pellets and stored at −80◦C for subsequent
quantification of TLR-2, TLR-4, MyD88, NF-κB p65 subunit,
caspase-1 and occludin expression. The detailed procedure
as well as primary and secondary antibodies employed are
described in Supplementary Material and in the Supplementary
Tables S1, S2.
Analysis of Bacterial Populations in Ileal
Samples
Total DNA extracted from ileal tissues was analyzed for
the mucosal-associated microbiota through 16S rDNA
metagenomics. Metagenomic analysis was performed with
MiSeq, Illumina platform at GenProbio SRL (Parma, Italy). The
methodology employed to extract DNA from tissues as well the
detailed procedure of 16S RNA gene amplification and MiSeq
sequencing are detailed in Supplementary Material.
In vitro Assays on NLRP3 Inflammasome
The human monocyte cell line THP-1, a well-established model
to study monocyte/macrophage functions, mechanisms, and
signaling pathways (Chanput et al., 2014), were cultured in RPMI
1640 media, supplemented with 10% fetal bovine serum, 100
units/ml penicillin, and 100 µg/ml streptomycin. Cells were
plated in 24-well plates at a density of 5 × 105 cells/well and
treated with phorbol 12-myristate 13-acetate (0.5 µM). After
3 h, the medium was removed, fresh medium was added, and
cells were incubated overnight (37◦C, 5% CO2). Cells were
primed with lipopolysaccharide (1 µg/ml, 4 h) to induce pro-
IL-1β expression before treatment with nigericin (a standard
NLRP3 inflammasome activator (10 µM, 1 h) (Mariathasan
et al., 2006), as described by Lopez-Castejon et al. (2013).
Lipopolysaccharide-primed cells were treated for 2 h with
rifaximin (25, 50, or 100 µM) before the addition of nigericin.
Thereafter, lipopolysaccharide-primed and nigericin-treated cells
(in the presence or absence of rifaximin) were incubated for a
total of 5 h before the collection of supernatants and cell lysates
for western blot assay of caspase-1 and measurement of IL-1β
concentrations, as described in Supplementary Material.
Statistical Analysis
Results are presented as mean ± standard error of mean (SEM).
The statistical significance of data was evaluated by one-way
analysis of variance (ANOVA) followed by post hoc analysis by
Student–Newman–Keuls test, and p-values less than 0.05 were
considered significant. All statistical calculations were performed
using GraphPad PrismTM 3.0 software (GraphPad, San Diego,
CA, United States).
RESULTS
Macroscopic Appearance of the
Intestine
A quantitative evaluation of the macroscopic injury elicited by
diclofenac was difficult to perform, due to the large mucosal
surface. However, diaphragm-like strictures and multiple
ulcerative lesions, both hallmark of NSAID-enteropathy, were
clearly present in rats given the NSAID, a picture not seen in
animals treated with diclofenac plus rifaximin or rifaximin alone.
Representative images, showing the macroscopic appearance of
small intestine in the different treatment groups, are displayed in
Supplementary Figure 1.
Microscopic Assessment of Intestinal
Damage
In the ileum from control animals, microscopic examination did
not reveal any type of lesion as was the case for rats treated
with rifaximin alone. Administration of diclofenac was associated
with the appearance of types 1, 2, and 3 lesions in the ileum
(Figure 1). In animals treated with diclofenac+rifaximin, all
types of NSAID-induced lesions were significantly decreased, as
compared with rats treated with diclofenac alone (Figure 1).
Hemoglobin Blood Levels
Mean hemoglobin concentration in the blood of control rats
was 16.0 g/dL. A similar figure was obtained in animals given
rifaximin alone. Compared to controls, diclofenac treatment
induced a significant blood loss, as mirrored by the drop of
blood hemoglobin concentration. This decrease was blunted
by co-administration of rifaximin (Figure 2A). However, the
hemoglobin levels of animals treated with both diclofenac
and rifaximin did not achieve those of control animals, since
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FIGURE 1 | Histological analysis of damage in the ileum of rats treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF,
50 mg/kg BID), or rifaximin (RIF) for 14 days. Representative pictures showing the microscopic appearance of ileal mucosa from control animals (A), as well as type
1 (B), type 2 (C) or type 3 (D) lesions, observed in animals treated with DIC. Effects of treatments on type 1 (E), type 2 (F), or type 3 (G) lesions. Each column
represents the mean ± SEM obtained from 10 animals. ∗p < 0.05, significant difference versus Control; ap < 0.05, significant difference vs. diclofenac alone.
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FIGURE 2 | Effects of vehicle (Control), diclofenac (DIC, 4 mg/kg BID),
diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days
on blood hemoglobin (A) or fecal calprotectin levels (B). Each column
represents the mean ± SEM obtained from 10 animals. ∗p < 0.05, significant
difference versus Control; ap < 0.05, significant difference versus diclofenac
alone.
upper gastrointestinal bleeding was likely not prevented by the
antibiotic.
Fecal Calprotectin Levels
The concentration of calprotectin in feces collected from control
animals was 2.03 ng/mg feces. Animals treated with diclofenac
displayed higher concentrations of fecal calprotectin (3.48 ng/mg
feces) (Figure 2B). In rats treated with diclofenac+rifaximin,
the levels of calprotectin were significantly reduced, approaching
control values. Animals treated with rifaximin alone displayed
levels of fecal calprotectin not significantly different from those
observed in control animals.
Tissue MPO Levels
Myeloperoxidase levels in ileal specimens taken from control
rats accounted for 5.98 ng/mg tissue (Figure 3A) and were
not modified by rifaximin alone. In animals treated with
diclofenac, MPO levels were significantly increased (23.57 ng/mg
tissue) (Figure 3A). In the ileum of rats treated with
diclofenac+rifaximin, MPO levels were lower as compared with
diclofenac alone and reverted back to the values of control
animals.
Tissue MDA Levels
In the ileum of control rats, the MDA concentration was
24.06 nmol/mg of tissue and, again, was not changed by
administration of rifaximin. Animals treated with diclofenac
displayed a significant increment of ileal MDA levels
(59.1 nmol/mg of tissue) (Figure 3B), which were significantly
reduced by co-administration of rifaximin.
Tissue TNF Levels
TNF levels in ileum from control rats accounted for 2.65 pg/mg
of tissue, and were not modified by treatment with rifaximin
alone. The administration of diclofenac was associated with
a significant increase in TNF concentration (Figure 3C).
Compared with rats given diclofenac alone, animals treated with
diclofenac+rifaximin showed a significant decrease in tissue TNF
concentrations. However, the observed values were still higher
(albeit not significantly different) than those observed in control
animals (Figure 3C).
Tissue IL-1β Levels
In control rats, IL-1β levels accounted for 13.2 pg/mg tissue and
were not affected by treatment with rifaximin alone (Figure 3D).
Rats treated with diclofenac displayed a significant increase in
tissue IL-1β levels, as compared with control animals. Under
these conditions, the concomitant administration of rifaximin
was associated with a normalization of ileal levels of the cytokine
(Figure 3D).
Expression of TLR-2, TLR-4, MyD88,
NF-κB p65 Subunit and Caspase-1
The expression of TLR-2 in small intestinal mucosa was enhanced
in animals treated with diclofenac, as compared to controls
(Figure 4A). Under these conditions, the co-administration
with rifaximin was associated with a significant decrease in the
receptor expression, while rifaximin administered alone had no
significant effect (Figure 4A).
Rats treated with diclofenac displayed also an increased
expression of TLR-4 in ileal mucosa. The administration of
diclofenac plus rifaximin elicited a significant reduction of TLR-
4 expression (Figure 4B), and again rifaximin alone did not
modify it.
Treatment with diclofenac resulted in a significant increment
of MyD88 expression in the ileal mucosa (Figure 4C). The
administration of rifaximin prevented the diclofenac-induced
MyD88 higher expression. In rats treated with rifaximin alone,
the levels of MyD88 expression were similar to those detected in
control animals (Figure 4C).
The expression of the p65 subunit was increased in the ileum
from rats treated with diclofenac, in comparison with control
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FIGURE 3 | Effects of vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days on
myeloperoxidase (MPO) (A), malondialdehyde (MDA) (B), tumor necrosis factor (TNF) (C), or interleukin-1β (IL-1β) (D) in the ileum. Each column represents the
mean ± SEM obtained from 10 animals. ∗p < 0.05, significant difference versus Control; ap < 0.05, significant difference versus diclofenac alone.
animals (Figure 4D). Under these experimental conditions, co-
treatment with rifaximin counterbalanced the higher expression
of p65, while rifaximin administration to control animals did not
affect the pattern of p65 expression (Figure 4D).
Expression of pro-caspase-1 (50 KD) in ileal tissue did not
differ among the experimental groups (Figure 4E). Cleaved
caspase-1 (p20, an autoprocessed fragment of caspase-1)
expression in ileal tissues from rats treated with diclofenac was
significantly increased, in comparison with controls (Figure 4F).
The concomitant administration of rifaximin prevented this
increase, while rifaximin administered alone did not exert any
significant effect (Figure 4F).
Expression of Occludin
Western blot assay revealed a well-detectable expression of
occludin in the ileal mucosa from control animals (Figure 5).
By contrast, in rats with diclofenac-induced enteropathy the
expression of occludin was markedly reduced. However, the
administration of rifaximin to animals with diclofenac-induced
enteropathy restored the occludin expression to values similar
to those detected in control animals. The administration of
rifaximin to normal rats did not significantly change occludin
expression (Figure 5).
Analysis of Bacterial Populations
In control animals, the relative abundance of Proteobacteria,
Firmicutes, Bacteroidetes, and Actinobacteria was 4.8, 84.6, 6.8,
and 0.6%, respectively. Treatment with diclofenac was associated
with an increase in the relative abundance of Proteobacteria
and Bacteroidetes and a decrease in Firmicutes (Figure 6A). The
administration of rifaximin to diclofenac-treated rats partially
counterbalanced these changes, while rifaximin alone did not
exert significant effects (Figure 6A). No relevant changes were
observed in the relative abundance of other phyla amongst the
different groups (Data not shown). When the genus Lactobacillus
was specifically analyzed, a substantial decrease was found after
diclofenac treatment. Rifaximin partially counterbalanced the
NSAID-induced decrease, while it did not affect the relative
abundance of Lactobacillus, when given alone (Figure 6B). No
substantial differences were observed in the prevalence of other
main bacterial species among the various groups (Data not
shown).
IL-1β Release and Caspase-1 Activation
in THP-1 Cells
Incubation with nigericin stimulated IL-1β release in
lipopolysaccharide-primed THP-1 cells (Figure 7A). Treatment
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FIGURE 4 | Western blot analysis of toll-like receptor-2 (TLR-2) (A), toll-like receptor-4 (TLR-4) (B), myeloid-differentiation primary response gene 88 (MyD88) (C),
activated nuclear factor-κB (p65) (D), pro-caspase-1 (E), and caspase-1 (p20) (F) in the ileum of rats treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID),
diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Each column represents the mean ± SEM obtained from 10 animals. ∗p < 0.05,
significant difference versus Control; ap < 0.05, significant difference versus diclofenac alone. Note that the beta actin signals in (A,D) result from stripping and
re-probing the same membrane, where TLR-2- and p65 proteins have been detected.
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FIGURE 5 | Western blot analysis of occludin in the ileum of rats treated with
vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin
(DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Each column
represents the mean ± SEM obtained from 10 animals. ∗p < 0.05, significant
difference versus Control; ap < 0.05, significant difference versus diclofenac
alone.
with rifaximin significantly reduced nigericin-induced IL-1β
release in a concentration-dependent fashion (Figure 7A).
THP-1 supernatants were assayed for cleavage of caspase-1.
Nigericin induced the cleavage of pro-caspase-1 into caspase-1
p20) (Figure 7B). The incubation of THP-1 cells with rifaximin
resulted in a decreased activation of caspase-1. By contrast,
rifaximin did not affect the expression of pro-caspase-1 in cell
lysates (Figure 7B).
DISCUSSION
Results of the present investigation clearly show that rifaximin
administration together with diclofenac protects the small bowel
from the damaging effect of this NSAID, in line with the findings
obtained in experimental animals with indomethacin (Ciobanu
et al., 2014; Fornai et al., 2016) and in healthy volunteers with
diclofenac (Scarpignato et al., 2017).
The Enteropathy Model
The experimental model, set up in our laboratory, was developed
to mimic clinical practice with NSAID chronic administration
in humans. Since elderly patients are more prone to develop
enteropathy (Lanas et al., 2012; Watanabe et al., 2013),
likely as consequence of an aging gut (Saffrey, 2014) and/or
co-morbidities and co-therapies (World Health Organization
[WHO], 2011), the present study was conducted on 40-week
old rats. Most experimental studies did use single, high doses of
NSAIDs (mainly indomethacin) to induce small bowel damage.
Under these experimental conditions, the mucosal injury is
usually represented by a number of bleeding lesions, affecting
deeply the intestinal wall (Abimosleh et al., 2013; Gyenge et al.,
2013; Yamamoto et al., 2014). This lesion pattern does not mirror
at all the one found during endoscopic investigations in long-
term NSAID users (Graham et al., 2005; Maiden et al., 2005;
Fujimori et al., 2010). In our experimental conditions, however,
diclofenac-induced small bowel damage consisted of diaphragm-
like strictures and multiple erosive lesions (along with anemia),
similarly to those found in patients receiving long-term NSAID
treatment (Maiden et al., 2005).
Pathophysiology of NSAID-Associated
Intestinal Lesions
More than 25 years ago, Bjarnason et al. (1987, 1992) first
showed that inflammation and blood loss (evaluated by means
of fecal excretion of 111In-labeled neutrophils and of 51Cr-
labeled red cells, respectively) are significantly increased in
patients with NSAID-enteropathy, the two parameters being
correlated to each other. Both inflammation and blood loss
were significantly reduced by 2–12 week treatment with
metronidazole (800 mg/day) (Bjarnason et al., 1992). These
findings suggested that NSAID-driven intestinal damage is
associated with significant mucosal inflammation, which could
be easily detected by the increase in fecal calprotectin (Tibble
et al., 1999; Maiden et al., 2005; Goldstein et al., 2007), and that
the main neutrophil chemo-attractants may be metronidazole-
sensitive bacteria.
Along with the intestinal lesions, in our experimental model,
inflammation and blood loss paralleled the findings observed in
humans. Indeed, MPO, TNF, and IL-1β tissue concentrations
as well as fecal calprotectin were significantly increased in
rats after diclofenac treatment. In addition, oxidative stress
(evaluated as lipid peroxidation, Janero, 1990) also increased in
the intestinal mucosa as a consequence of tissue damage. Co-
administration of rifaximin with diclofenac counterbalanced all
these changes whereas the antibiotic alone did not affect any of
these parameters.
Several studies have shown that almost all non-selective
NSAIDs induce an early (within 24 h of ingestion) increase of
intestinal permeability in humans, an effect that persists after
chronic administration (Davies, 1998; Bjarnason and Takeuchi,
2009). Impairment of enteric mucosal barrier represents the
primum movens of a series of pathophysiologic events, leading
to mucosal damage. Indeed, the disrupted intercellular tight-
junctions (TJs) facilitate the entrance and action of bacteria
or bacterial antigens (as well as other luminal factors), which
induce a higher expression and enhanced release of pro-
inflammatory cytokines from the intestinal epithelium. Occludin,
a 65-kDa tetraspan integral membrane protein, contributes
to TJ stabilization and optimal barrier function, and its
dysregulation is an established pathophysiologic hallmark of
clinical conditions (like NSAID-enteropathy) with underlying
alterations of intestinal permeability (Feldman et al., 2005;
Cummins, 2012). In this connection, we found a remarkable
down-regulation of this TJ protein in the ileal tissue of
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FIGURE 6 | (A) Relative abundance of Proteobacteria, Firmicutes, Bacteroidetes, and Actinobacteria and (B) prevalence of Lactobacillus spp. in the ileum of rats
treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Each column represents
the mean ± SEM obtained from 10 animals. ∗p < 0.05, significant difference versus Control; ap < 0.05, significant difference versus diclofenac alone.
diclofenac-treated animals. This finding is in line with the
decrease in occludin expression induced by indomethacin
in Caco-2 (human epithelial colorectal adenocarcinoma) cell
monolayers (Carrasco-Pozo et al., 2013).
Disruption of the intestinal TJ barrier is an important
pathogenic mechanism leading to increased epithelial
penetration of luminal noxious molecules, with consequent
activation of the mucosal immune system and subsequent
development of intestinal inflammation (Suzuki, 2013).
The release of pro-inflammatory cytokines causes further
disturbances of the intestinal barrier, thus amplifying immune
activation and the inflammatory reaction (Al-Sadi et al.,
2009). In our experimental model, together with increased
ileal concentrations of TNF and IL-1β, we observed a higher
expression of both TLR-4 and TLR-2. In an acute model
of NSAID-enteropathy, Watanabe et al. (2008) reported
up-regulation of TLR-4 suggesting the involvement of
Gram-negative bacteria in the pathogenesis of mucosal
inflammation and intestinal lesions. Our findings, showing
TLR-2 higher expression, suggest a role also for Gram-positive
microorganisms. Indeed, TLR-4 was found to be a receptor for
LPS (major component of the outer membrane of Gram-negative
bacteria) while TLR-2 binds peptidoglycan and lipoteichoic
acid (major cell wall components of Gram-positive bacteria)
(Takeda et al., 2003; McGuire and Arthur, 2015). Stimulation of
all TLRs activates MyD88-dependent Nuclear Factor-κB (NF-κB)
signaling, which plays a critical role for an effective immune
response (McGuire and Arthur, 2015), a pathway observed under
our experimental conditions. However, while TLR-2-mediated
NF-κB activation is fully MyD88-dependent, LPS activates both
MyD88-dependent and independent pathways (Takeuchi and
Akira, 2001).
TLR higher expression, along with downstream activation
of the NF-κB pathway, suggests the involvement of the
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FIGURE 7 | Lipopolysaccharide-primed THP-1 cells treated with rifaximin (RIF,
25, 50, or 100 µM) before the addition of nigericin (10 µM). (A) Effect of
rifaximin (RIF) on interleukin-1β (IL-1β) release in cell supernatants. (B) Effect
of rifaximin (RIF) on caspase-1 p20 expression in cell supernatants as well as
on pro-caspase-1 expression in cell lysates. Each column represents the
mean ± SEM value obtained from four separate experiments. ∗p < 0.05,
significant difference versus cells treated with nigericin alone.
NLRP3 inflammasome in the pathogenesis of NSAID-associated
intestinal inflammation. Indeed, consistent with this hypothesis,
in diclofenac-treated animals, we found an increased cleavage
of pro-caspase 1 into caspase-1, followed by elevated ileal
concentrations of IL-1β, a well-established pattern of canonical
NLRP3 inflammasome activation (Pellegrini et al., 2017). In line
with these findings, Higashimori et al. (2016) observed – in an
acute model of indomethacin-induced enteropathy – an increase
in mRNA expression of the NLRP3 inflammasome, together with
an increase in tissue levels of caspase-1 and IL-1β.
Metagenomic analysis revealed that diclofenac administration
induced an increase in the relative abundance of Proteobacteria
and Bacteroidetes. Recent investigations reported a marked
increase in Proteobacteria in naproxen-treated (Syer et al.,
2015) and indomethacin-treated (Fornai et al., 2016) rats, and
suggested that these microbial changes might contribute to
NSAID-induced intestinal damage. The marked decrease in the
Lactobacillus genus found in diclofenac-treated animals parallels
its almost complete depletion observed in elderly NSAID users
(Makivuokko et al., 2010).
In the healthy bowel, commensal non-pathogenic bacteria
interact with the host mucosa, co-regulating the function
of mucosal barrier. In this context, Lactobacillus deficiency
may contribute to the development of NSAID-enteropathy.
Indeed, these probiotic bacteria exert a protective effect on the
intestinal barrier and reduce intestinal permeability (Mennigen
and Bruewer, 2009; Liu et al., 2014), and several experimental and
human studies (for review see Syer et al., 2015) have shown their
ability to prevent NSAID-induced small bowel lesions.
Mechanisms of Rifaximin Mucosal
Protection
The entero-protective effect of rifaximin, observed in this
study, was associated with a decrease in tissue inflammation
(as reflected by the reduced MPO, TNF, and IL-1β mucosal
concentrations) and oxidative stress (mirrored by lowed MDA
tissue levels). Along the same lines, diclofenac-induced blood loss
and increased fecal calprotectin concentrations were significantly
reduced by rifaximin. These findings are in line with the
results previously obtained in our laboratories in the setting of
indomethacin-enteropathy (Fornai et al., 2016).
New findings in the present investigation concern the
reversal by rifaximin of the TLR-2 and TLR-4 higher expression
and downstream pro-inflammatory signaling, accompanied by
complete recovery of the TJ protein occludin, the expression
of which was severely impaired by diclofenac administration.
Rifaximin also partially reverted the diclofenac-induced shift
of bacterial phyla toward an increase in Proteobacteria and
Bacteroidetes abundance. Most importantly, the drug also
increased the proportion of Lactobacilli, a genus depleted by the
NSAID.
The nature of the anti-inflammatory activity of rifaximin
could be the consequence of its anti-microbial properties (and
therefore indirect) or intrinsic to the pharmacologic properties of
the drug (i.e., a direct one). Drugs belonging to the rifamycin class
exert anti-inflammatory activity, which seems to be independent
from the anti-microbial properties. Rifamycins indeed inhibit
human neutrophil functions (Spisani et al., 1997, 1998) and intra-
articular rifamycin SV was shown to be effective in patients
with chronic arthritides, like juvenile rheumatoid arthritis and
ankylosing spondylitis (Caruso, 1997).
Some studies, including our own, have shown the rifaximin
ability of inhibiting inflammatory cytokine release in the
intestinal mucosa, induced by chronic stress (Xu et al., 2014)
or NSAID administration (Fornai et al., 2016) in rats. In
addition, the drug reduced cytokine production from LPS-
activated THP-1 monocytes in vitro (Rosette et al., 2013),
thus suggesting an intrinsic anti-inflammatory activity. This
last investigation, however, did not provide any mechanistic
explanation for the anti-inflammatory effect of rifaximin. Since
we (this study) and others (Higashimori et al., 2016) have
shown that NSAID-associated intestinal mucosal inflammation
is mediated via NLRP3 inflammasome activation, an effect
counterbalanced by rifaximin administration, we hypothesized
that the anti-inflammatory activity of this antibiotic could rely
on a modulation of NLRP3 inflammasome activity. Therefore,
rifaximin was tested in an in vitro cell system (LPS-primed THP-1
cells stimulated by nigericin) for its ability to modulate NLRP3
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inflammasome pathway. In accordance with our hypothesis, the
drug reduced IL-1β production in a dose-dependent fashion, this
effect being associated with inhibition of the up-stream caspase-
1 activation. This original observation provides compelling
evidence for an intrinsic anti-inflammatory activity of rifaximin.
Rifaximin for Prevention of
NSAID-Enteropathy in Clinical Practice
Recent evidence is consistent with the idea that – besides
non-anti-microbial activities (e.g., anti-inflammatory action) –
rifaximin displays also “eubiotic” properties. In patients
with inflammatory conditions of the digestive system
(inflammatory bowel disease, colonic diverticular disease or
hepatic encephalopathy), this antibiotic – conversely from
systemic anti-microbials – did not change the overall human
colonic microbiota, but actually increased the relative abundance
of Bifidobacteria and Lactobacilli (Maccaferri et al., 2010; Xu
et al., 2014; Ponziani et al., 2016).
NSAID therapy is often required in long-term, especially
in chronic inflammatory conditions. As a consequence, also
prevention of NSAID gastrointestinal injury needs to be long-
term and should be accomplished with effective and safe drugs.
Rifaximin proved to be extremely safe. Indeed, its minimal, if
any, systemic absorption translates into an adverse event profile,
overlapping that of placebo, even after 6-month continuous
administration (Bass et al., 2010). In addition to the lack of
emergence of pathogenic bacteria, occurrence of opportunistic
infections, and alteration of the overall microbiota, no clinically
relevant changes in bacterial sensitivity to other antibiotic classes
have been reported (DuPont et al., 2016; Pimentel et al., 2017).
In summary, co-administration of rifaximin with diclofenac
prevents NSAID-induced small bowel damage in rats. These
results and those of a recent proof-of-concept study in humans
(Scarpignato et al., 2017) suggest that targeting enteric bacteria
and mucosal inflammation by a poorly absorbed antibiotic, such
as rifaximin, is an attractive therapeutic avenue for the prevention
of NSAID-enteropathy (Scarpignato, 2008).
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